PDUFA Talks: Four-Phase Review Flops; Automatic Extensions Back On Table
Executive Summary
FDA and industry have moved to a more pointed debate of automatic review deadline extensions after the agency decided to drop its four-phase review process proposal.
You may also be interested in...
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
NMEs and novel biologics will see reviews allotted two additional months under the revised model launching Oct. 1. Industry expects to gain more communication and first-cycle approvals, while FDA hopes it can receive more complete applications at submission and improve transparency.
FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty
Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.
FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty
Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.